CLARITHROMYCIN- clarithromycin tablet, film coated, extended release
Lannett Company, Inc.

----------

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use CLARITHROMYCIN EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for CLARITHROMYCIN EXTENDED-RELEASE TABLETS.

CLARITHROMYCIN Extended-release tablets, for oral use


-------------------- RECENT MAJOR CHANGES ---------------------

Contraindications, Lomitapide, Lovastatin, and Simvastatin (4.5) 9/2019
Warnings and Precautions, QT Prolongation (5.2) 11/2018
Warnings and Precautions, Serious Adverse Reactions Due to Concomitant Use with Other Drugs (5.4) 9/2019
Warnings and Precautions, Embryo-fetal Toxicity (5.7) 12/2018

----------------- INDICATIONS AND USAGE -----------------------
Clarithromycin Extended-release Tablets, USP is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following:

- Acute Bacterial Exacerbation of Chronic Bronchitis in Adults (1.1)
- Acute Maxillary Sinusitis (1.2)
- Community-Acquired Pneumonia (1.3)

Limitations of Use
Clarithromycin Extended-release Tablets, USP is indicated only for acute bacterial exacerbation of chronic bronchitis, acute maxillary sinusitis, and community-acquired pneumonia in adults. (1.9)

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clarithromycin Extended-release Tablets, USP and other antibacterial drugs, Clarithromycin Extended-release Tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.9)

------------------ DOSAGE AND ADMINISTRATION -------------------

- Adults: Clarithromycin Extended-release tablets 1 gram every 24 hours for 7–14 days (2.2)
- Reduce dose in moderate renal impairment with concomitant atazanavir or ritonavir-containing regimens and in severe renal impairment (2.6)

------------------ DOSAGE FORMS AND STRENGTHS ------------------

- Extended-release Tablets: 500 mg (3)

------------------- CONTRAINDICATIONS ---------------------------

- Hypersensitivity to clarithromycin or any macrolide drug (4.1)
- Cisapride and pimozide (4.2)
- History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin (4.3)
- Colchicine in renal or hepatic impairment (4.4)
- Lomitapide, lovastatin, and simvastatin (4.5)
- Ergot alkaloids (ergotamine or dihydroergotamine) (4.6)

------------------ WARNINGS AND PRECAUTIONS ---------------------

- Severe Acute Hypersensitivity Reactions: Discontinue clarithromycin if occurs (5.1)
- **QT Prolongation:** Avoid clarithromycin in patients with known QT prolongation or receiving drugs known to prolong the QT interval, ventricular arrhythmia (*torsades de pointes*), hypokalemia/hypomagnesemia, significant bradycardia, or taking Class IA or III antiarrhythmics (5.2)
- **Hepatotoxicity:** Discontinue if signs and symptoms of hepatitis occur (5.3)
- **Serious adverse reactions** can occur due to drug interactions of clarithromycin with colchicine, some lipid-lowering agents, some calcium channel blockers, and other drugs (5.4)
- **Risk of all-cause mortality** one year or more after the end of treatment in patients with coronary artery disease. Balance this potential risk with the treatment benefits when prescribing clarithromycin tablets in these patients. (5.5)
- **Clostridium difficile associated diarrhea (CDAD):** Evaluate if diarrhea occurs (5.6)
- **Embryo-Fetal Toxicity:** Based on animal findings, clarithromycin is not recommended for use in pregnant women except in clinical circumstances where no alternative therapy is appropriate (5.7)
- **Exacerbation of myasthenia gravis** has been reported in patients receiving clarithromycin therapy. (5.8)

---

**ADVERSE REACTIONS**

Most frequent adverse reactions for both adult and pediatric populations in clinical trials: abdominal pain, diarrhea, nausea, vomiting, dysgeusia (6.1)

To report SUSPECTED ADVERSE REACTIONS, Lannett Company, Inc. at 1-844-834-0530 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

---

**DRUG INTERACTIONS**

Co-administration of clarithromycin can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy. (4, 5.2, 5.4, 7)

---

**USE IN SPECIFIC POPULATIONS**

*Geriatric:* Increased risk of *torsades de pointes* (8.5)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 11/2019

---

**FULL PRESCRIBING INFORMATION: CONTENTS**

1 **INDICATIONS AND USAGE**
   1.1 Acute Bacterial Exacerbation of Chronic Bronchitis
   1.2 Acute Maxillary Sinusitis
   1.3 Community-Acquired Pneumonia
   1.9 Limitations of Use
   1.10 Usage

2 **DOSAGE AND ADMINISTRATION**
   2.1 Important Administration Instructions
   2.2 Adult Dosage
   2.6 Dosage Adjustment in Patients with Renal Impairment
   2.7 Dosage Adjustment Due to Drug Interactions

3 **DOSAGE FORMS AND STRENGTHS**

4 **CONTRAINdications**
   4.1 Hypersensitivity
   4.2 Cisapride and Pimozide
   4.3 Cholestatic Jaundice/Hepatic Dysfunction
   4.4 Colchicine
   4.5 Lomitapide, Lovastatin, and Simvastatin
   4.6 Ergot Alkaloids
   4.7 Contraindications for Co-administered Drugs

5 **WARNINGS AND PRECAUTIONS**
   5.1 Severe Acute Hypersensitivity Reactions
   5.2 QT Prolongation
5.3 Hepatotoxicity
5.4 Serious Adverse Reactions Due to Concomitant Use with Other Drugs
5.5 All-Cause Mortality in Patients With Coronary Artery Disease 1 to 10 Years After Clarithromycin Exposure
5.6 *Clostridium difficile* Associated Diarrhea
5.7 Embryo-Fetal Toxicity
5.8 Exacerbation of Myasthenia Gravis
5.9 Development of Drug Resistant Bacteria

6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
6.2 Postmarketing Experience

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Lactation
8.3 Females and Males of Reproductive Potential
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Renal and Hepatic Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.3 Pharmacokinetics
12.4 Microbiology

13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
13.2 Animal Toxicology and/or Pharmacology

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION
* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Acute Bacterial Exacerbation of Chronic Bronchitis
Clarithromycin Extended-release Tablets, USP are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to *Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae*[see Indications and Usage (1.4)]

1.2 Acute Maxillary Sinusitis
Clarithromycin Extended-release Tablets, USP (in adults) are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to *Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae*[see Indications and Usage (1.4)]

1.3 Community-Acquired Pneumonia
Clarithromycin Extended-release Tablets, USP are indicated [see Indications and Usage (1.4)] for the
treatment of mild to moderate infections caused by susceptible isolates due to:

- *Haemophilus influenzae* (in adults)
- *Haemophilus parainfluenzae* (in adults)
- *Moraxella catarrhalis* (in adults)
- *Mycoplasma pneumoniae, Streptococcus pneumoniae, Chlamydophila pneumoniae* (in adults)

### 1.9 Limitations of Use

Clarithromycin Extended-release Tablets, USP are indicated only for acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, and community-acquired pneumonia in adults. The efficacy and safety of Clarithromycin Extended-release Tablets, USP in treating other infections for which other formulations of clarithromycin are approved have not been established.

There is resistance to macrolides in certain bacterial infections caused by *Streptococcus pneumoniae* and *Staphylococcus aureus*. Susceptibility testing should be performed when clinically indicated.

### 1.10 Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clarithromycin Extended-release Tablets, USP and other antibacterial drugs, Clarithromycin Extended-release Tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

### 2 DOSAGE AND ADMINISTRATION

#### 2.1 Important Administration Instructions

Clarithromycin Extended-release Tablets, USP should be taken with food. Swallow Clarithromycin Extended-release Tablets, USP whole; do not chew, break or crush Clarithromycin Extended-release Tablets, USP.

#### 2.2 Adult Dosage

The recommended dosages of Clarithromycin Extended-release Tablets, USP for the treatment of mild to moderate infections in adults are listed in Table 1.

<table>
<thead>
<tr>
<th>Infection</th>
<th>Dosage (every 24 hours)</th>
<th>Duration (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute bacterial exacerbation of chronic bronchitis</td>
<td>1 gram</td>
<td>7</td>
</tr>
<tr>
<td>Acute maxillary sinusitis</td>
<td>1 gram</td>
<td>14</td>
</tr>
<tr>
<td>Community-acquired pneumonia</td>
<td>1 gram</td>
<td>7</td>
</tr>
</tbody>
</table>

#### 2.6 Dosage Adjustment in Patients with Renal Impairment

See Table 2 for dosage adjustment in patients with moderate or severe renal impairment with or without
concomitant atazanavir or ritonavir-containing regimens [see Drug Interactions (7)].

### Table 2. Clarithromycin Dosage Adjustments in Patients with Renal Impairment

<table>
<thead>
<tr>
<th>Patients with severe renal impairment (CL\textsubscript{CR} of &lt;30 mL/min)</th>
<th>Recommended Clarithromycin Dosage Reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduce the dosage of clarithromycin by 50%</td>
<td></td>
</tr>
</tbody>
</table>

| Patients with moderate renal impairment (CL\textsubscript{CR} of 30 to 60 mL/min) taking concomitant atazanavir or ritonavir-containing regimens | Reduce the dosage of clarithromycin by 50% |

| Patients with severe renal impairment (CL\textsubscript{CR} of <30 mL/min) taking concomitant atazanavir or ritonavir-containing regimens | Reduce the dosage of clarithromycin by 75% |

### 2.7 Dosage Adjustment Due to Drug Interactions

Decrease the dose of clarithromycin by 50% when co-administered with atazanavir [see Drug Interactions (7)]. Dosage adjustments for other drugs when co-administered with clarithromycin may be recommended due to drug interactions [see Drug Interactions (7)].

### 3 DOSAGE FORMS AND STRENGTHS

Clarithromycin Extended-release Tablets, USP are supplied as white or off-white, capsular-shaped film-coated 500 mg tablets debossed “S58” on one side and blank on the other side.

### 4 CONTRAINDICATIONS

#### 4.1 Hypersensitivity

Clarithromycin is contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [see Warnings and Precautions (5.1)].

#### 4.2 Cisapride and Pimozide

Concomitant administration of clarithromycin with cisapride and pimozide is contraindicated [see Drug Interactions (7)].

There have been postmarketing reports of drug interactions when clarithromycin is co-administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes) most likely due to inhibition of metabolism of these drugs by clarithromycin. Fatalities have been reported.

#### 4.3 Cholestatic Jaundice/Hepatic Dysfunction

Clarithromycin is contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin.

#### 4.4 Colchicine

Concomitant administration of clarithromycin and colchicine is contraindicated in patients with renal or hepatic impairment.

#### 4.5 Lomitapide, Lovastatin, and Simvastatin

Concomitant administration of clarithromycin with lomitapide is contraindicated due to potential for markedly increased transaminases [see Warnings and Precautions (5.4) and Drug Interactions (7)].
Concomitant administration of clarithromycin with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [see Warnings and Precautions (5.4) and Drug Interactions (7)].

4.6 Ergot Alkaloids
Concomitant administration of clarithromycin and ergotamine or dihydroergotamine is contraindicated [see Drug Interactions (7)].

4.7 Contraindications for Co-administered Drugs
For information about contraindications of other drugs indicated in combination with clarithromycin, refer to their full prescribing information (contraindications section).

5 WARNINGS AND PRECAUTIONS

5.1 Severe Acute Hypersensitivity Reactions
In the event of severe acute hypersensitivity reactions, such as anaphylaxis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), Henoch-Schonlein purpura, and acute generalized exanthematous pustulosis, discontinue clarithromycin therapy immediately and institute appropriate treatment.

5.2 QT Prolongation
- Clarithromycin has been associated with prolongation of the QT interval and infrequent cases of arrhythmia. Cases of torsades de pointes have been spontaneously reported during postmarketing surveillance in patients receiving clarithromycin. Fatalities have been reported.

Avoid clarithromycin in the following patients:
- patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes
- patients receiving drugs known to prolong the QT interval [see also Contraindications (4.2)]
- patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia and in patients receiving Class IA (e.g., quinidine, procainamide, disopyramide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents.

Elderly patients may be more susceptible to drug-associated effects on the QT interval [see Use in Specific Populations (8.5)].

5.3 Hepatotoxicity
Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported with clarithromycin. This hepatic dysfunction may be severe and is usually reversible. In some instances, hepatic failure with fatal outcome has been reported and generally has been associated with serious underlying diseases and/or concomitant medications. Symptoms of hepatitis can include anorexia, jaundice, dark urine, pruritus, or tender abdomen. Discontinue clarithromycin immediately if signs and symptoms of hepatitis occur.

5.4 Serious Adverse Reactions Due to Concomitant Use with Other Drugs
Drugs metabolized by CYP3A4: Serious adverse reactions have been reported in patients taking clarithromycin concomitantly with CYP3A4 substrates. These include colchicine toxicity with colchicine; markedly increased transaminases with lomitapide; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; hypoglycemia and cardiac arrhythmias (e.g., torsades de pointes) with
disopyramide; and hypotension and acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem, nifedipine). Most reports of acute kidney injury with calcium channel blockers metabolized by CYP3A4 involved elderly patients 65 years of age or older. Use clarithromycin with caution when administered concurrently with medications that induce the cytochrome CYP3A4 enzyme. The use of clarithromycin with lomitapide, simvastatin, lovastatin, ergotamine, or dihydroergotamine is contraindicated [see Contraindications (4.5,4.6) and Drug Interactions (7)].

**Colchicine:** Life-threatening and fatal drug interactions have been reported in patients treated with clarithromycin and colchicine. Clarithromycin is a strong CYP3A4 inhibitor and this interaction may occur while using both drugs at their recommended doses. If co-administration of clarithromycin and colchicine is necessary in patients with normal renal and hepatic function, reduce the dose of colchicine. Monitor patients for clinical symptoms of colchicine toxicity. Concomitant administration of clarithromycin and colchicine is contraindicated in patients with renal or hepatic impairment [see Contraindications (4.4) and Drug Interactions (7)].

**Lomitapide:** Concomitant use of clarithromycin with lomitapide is contraindicated [see Contraindications (4.5)]. Lomitapide is metabolized by CYP3A4, and concomitant treatment with clarithromycin increases the plasma concentration of lomitapide, which increases the risk of elevation in transaminases [see Drug Interactions (7)]. If treatment with clarithromycin cannot be avoided, therapy with lomitapide must be suspended during the course of treatment.

**HMG-CoA Reductase Inhibitors (statins):** Concomitant use of clarithromycin with lovastatin or simvastatin is contraindicated [see Contraindications (4.5)] as these statins are extensively metabolized by CYP3A4, and concomitant treatment with clarithromycin increases their plasma concentration, which increases the risk of myopathy, including rhabdomyolysis. Cases of rhabdomyolysis have been reported in patients taking clarithromycin concomitantly with these statins. If treatment with clarithromycin cannot be avoided, therapy with lovastatin or simvastatin must be suspended during the course of treatment.

Exercise caution when prescribing clarithromycin with atorvastatin or pravastatin. In situations where the concomitant use of clarithromycin with atorvastatin or pravastatin cannot be avoided, atorvastatin dose should not exceed 20 mg daily and pravastatin dose should not exceed 40 mg daily. Use of a statin that is not dependent on CYP3A metabolism (e.g. fluvastatin) can be considered. It is recommended to prescribe the lowest registered dose if concomitant use cannot be avoided.

**Oral Hypoglycemic Agents/Insulin:** The concomitant use of clarithromycin and oral hypoglycemic agents and/or insulin can result in significant hypoglycemia. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of CYP3A enzyme by clarithromycin may be involved and could cause hypoglycemia when used concomitantly. Careful monitoring of glucose is recommended [see Drug Interactions (7)].

**Quetiapine:** Use quetiapine and clarithromycin concomitantly with caution. Co-administration could result in increased quetiapine exposure and quetiapine related toxicities such as somnolence, orthostatic hypotension, altered state of consciousness, neuroleptic malignant syndrome, and QT prolongation. Refer to quetiapine prescribing information for recommendations on dose reduction if co-administered with CYP3A4 inhibitors such as clarithromycin [see Drug Interactions (7)].

**Oral Anticoagulants:** There is a risk of serious hemorrhage and significant elevations in INR and prothrombin time when clarithromycin is co-administered with warfarin. Monitor INR and prothrombin times frequently while patients are receiving clarithromycin and oral anticoagulants concurrently [see Drug Interactions (7)].

**Benzodiazepines:** Increased sedation and prolongation of sedation have been reported with concomitant administration of clarithromycin and triazolobenzodiazepines, such as triazolam and midazolam [see Drug Interactions (7)].

5.5 **All-Cause Mortality in Patients With Coronary Artery Disease 1 to 10 Years After**
Clarithromycin Exposure

In one clinical trial evaluating treatment with clarithromycin on outcomes in patients with coronary artery disease, an increase in risk of all-cause mortality one year or more after the end of treatment was observed in patients randomized to receive clarithromycin. The cause of the increased risk has not been established. Other epidemiologic studies evaluating this risk have shown variable results [see Adverse Reactions (6.1)]. Considering balancing this potential risk with the treatment benefits when prescribing clarithromycin in patients who have suspected or confirmed coronary artery disease.

5.6 Clostridium difficile Associated Diarrhea

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clarithromycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

5.7 Embryo-Fetal Toxicity

Based on findings from animal studies, clarithromycin is not recommended for use in pregnant women except in clinical circumstances where no alternative therapy is appropriate. If clarithromycin is used during pregnancy, or if pregnancy occurs while the patient is taking this drug, the patient should be apprised of the potential hazard to the fetus. Clarithromycin demonstrated adverse effects on pregnancy outcome and/or embryo fetal development, including fetal malformations, in pregnant animals administered oral clarithromycin [see Use in Specific Populations (8.1)].

5.8 Exacerbation of Myasthenia Gravis

Exacerbation of symptoms of myasthenia gravis and new onset of symptoms of myasthenic syndrome has been reported in patients receiving clarithromycin therapy.

5.9 Development of Drug Resistant Bacteria

Prescribing clarithromycin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

6 ADVERSE REACTIONS

The following serious adverse reactions are described below and elsewhere in the labeling:

- Acute Hypersensitivity Reactions [see Warnings and Precautions (5.1)]
- QT Prolongation [see Warnings and Precautions (5.2)]
- Hepatotoxicity [see Warnings and Precautions (5.3)]
- Serious Adverse Reactions Due to Concomitant Use with Other Drugs [see Warnings and Precautions (5.4)]
• Clostridium difficile Associated Diarrhea [see Warnings and Precautions (5.6)]

• Exacerbation of Myasthenia Gravis [see Warnings and Precautions (5.8)]

6.1 Clinical Trials Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Based on pooled data across all indications, the most frequent adverse reactions for both adult and pediatric populations observed in clinical trials are abdominal pain, diarrhea, nausea, vomiting and dysgeusia. Also reported were dyspepsia, liver function test abnormal, anaphylactic reaction, candidiasis, headache, insomnia, and rash.

The subsequent subsections list the most common adverse reactions for prophylaxis and treatment of mycobacterial infections and duodenal ulcer associated with H. pylori infection. In general, these profiles are consistent with the pooled data described above.

Prophylaxis of Mycobacterial Infections

In AIDS patients treated with clarithromycin over long periods of time for prophylaxis against M. avium, it was often difficult to distinguish adverse reactions possibly associated with clarithromycin administration from underlying HIV disease or intercurrent illness. Median duration of treatment was 10.6 months for the clarithromycin group and 8.2 months for the placebo group.

### Table 4. Incidence Rates (%) of Selected Adverse Reactions in Immunocompromised Adult Patients Receiving Prophylaxis Against M. avium Complex

<table>
<thead>
<tr>
<th>Body System b</th>
<th>Clarithromycin (n=339)</th>
<th>Placebo (n=339)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adverse Reaction</strong></td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td><strong>Body as a Whole</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>5%</td>
<td>4%</td>
</tr>
<tr>
<td>Headache</td>
<td>3%</td>
<td>1%</td>
</tr>
<tr>
<td><strong>Digestive</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>8%</td>
<td>4%</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>4%</td>
<td>3%</td>
</tr>
<tr>
<td>Flatulence</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Nausea</td>
<td>11%</td>
<td>7%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>6%</td>
<td>3%</td>
</tr>
<tr>
<td><strong>Skin &amp; Appendages</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>3%</td>
<td>4%</td>
</tr>
<tr>
<td><strong>Special Senses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taste Perversion</td>
<td>8% c</td>
<td>0.3%</td>
</tr>
</tbody>
</table>

a Includes those events possibly or probably related to study drug and excludes concurrent conditions
b 2% or greater Adverse Reaction Incidence Rates for either treatment group
c Significant higher incidence compared to the placebo-treated group

Discontinuation due to adverse reactions occurred in 18% of patients receiving clarithromycin compared to 17% of patients receiving placebo in this trial. Primary reasons for discontinuation in clarithromycin treated patients include headache, nausea, vomiting, depression, and taste perversion.
Changes in Laboratory Values

Selected laboratory adverse experiences that were reported during therapy in greater than 2% of adult patients treated with clarithromycin in a randomized double-blind clinical trial involving 682 patients are presented in Table 5.

In immunocompromised patients receiving prophylaxis against *M. avium*, evaluations of laboratory values were made by analyzing those values outside the seriously abnormal value (i.e., the extreme high or low limit) for the specified test.

<table>
<thead>
<tr>
<th>Table 5. Percentage of Patients a Exceeding Extreme Laboratory Values in Patients Receiving Prophylaxis Against <em>M. avium</em> Complex</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clarithromycin 500 mg twice a day</strong></td>
</tr>
<tr>
<td>WBC Count</td>
</tr>
<tr>
<td>SGOT</td>
</tr>
<tr>
<td>SGPT</td>
</tr>
</tbody>
</table>

*Includes only patients with baseline values within the normal range or borderline high (hematology variables) and within normal range or borderline low (chemistry variables)*

*ULN= Upper Limit of Normal*

Treatment of Mycobacterial Infections

The adverse reaction profiles for both the 500 mg and 1000 mg twice a day dose regimens were similar.

In AIDS patients and other immunocompromised patients treated with the higher doses of clarithromycin over long periods of time for mycobacterial infections, it was often difficult to distinguish adverse reactions possibly associated with clarithromycin administration from underlying signs of HIV disease or intercurrent illness.

The following analysis summarizes experience during the first 12 weeks of therapy with clarithromycin. Data are reported separately for trial 1 (randomized, double-blind) and trial 2 (open-labeled, compassionate use) and also combined. Adverse reactions were reported less frequently in trial 2, which may be due in part to differences in monitoring between the two studies.

In adult patients receiving clarithromycin 500 mg twice a day, the most frequently reported adverse reactions, considered possibly or possibly related to study drug, with an incidence of 5% or greater, are listed below (Table 6). Approximately 8% of the patients who received 500 mg twice a day and 12% of the patients who received 1000 mg twice a day discontinued therapy due to drug related adverse reactions during the first 12 weeks of therapy; adverse reactions leading to discontinuation in at least 2 patients included nausea, vomiting, abdominal pain, diarrhea, rash, and asthenia.

| Table 6. Selected Treatment-Related a Adverse Reaction Incidence Rates (%) in Immunocompromised Adult Patients During the First 12 Weeks of Therapy with 500 mg Twice a Day Clarithromycin Dose |
|-------------------------------|-------------|-------------|-------------|
| **Adverse Reaction** | **Trial 1** | **Trial 2** | **Combined** |
| | *(n=53)* | *(n=255)* | *(n=308)* |
| Abdominal Pain | 8 | 2 | 3 |
| Diarrhea | 9 | 2 | 3 |
| Flatulence | 8 | 0 | 1 |
A limited number of pediatric AIDS patients have been treated with clarithromycin suspension for mycobacterial infections. The most frequently reported adverse reactions excluding those due to the patient's concurrent conditions were consistent with those observed in adult patients.

Changes in Laboratory Values

In the first 12 weeks of starting on clarithromycin 500 mg twice a day, 3% of patients has SGOT increases and 2% of patients has SGPT increases >5 times the upper limit of normal in trial 2 (469 enrolled adult patients) while trial 1 (154 enrolled patients) had no elevation of transaminases. This includes only patients with baseline values within the normal range or borderline low.

Duodenal ulcer associated with H. pylori Infection

In clinical trials using combination therapy with clarithromycin plus omeprazole and amoxicillin, no adverse reactions specific to the combination of these drugs have been observed. Adverse reactions that have occurred have been limited to those that have been previously reported with clarithromycin, omeprazole or amoxicillin.

The adverse reaction profiles are shown below (Table 7) for four randomized double-blind clinical trials in which patients received the combination of clarithromycin 500 mg three times a day, and omeprazole 40 mg daily for 14 days, followed by omeprazole 20 mg once a day, (three studies) or 40 mg once a day (one study) for an additional 14 days. Of the 346 patients who received the combination, 3.5% of patients discontinued drug due to adverse reactions.

### Table 7. Adverse Reactions with an Incidence of 3% or Greater

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Clarithromycin + Omeprazole (n=346) % of Patients</th>
<th>Omeprazole (n=355) % of Patients</th>
<th>Clarithromycin (n=166) % of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taste Perversion</td>
<td>15</td>
<td>1</td>
<td>16</td>
</tr>
<tr>
<td>Nausea</td>
<td>5</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Headache</td>
<td>5</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>4</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>Vomiting</td>
<td>4</td>
<td>&lt;1</td>
<td>1</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Infection</td>
<td>3</td>
<td>4</td>
<td>2</td>
</tr>
</tbody>
</table>

a Only two of four studies

Changes in Laboratory Values

Changes in laboratory values with possible clinical significance in patients taking clarithromycin and omeprazole in four randomized double-blind trials in 945 patients are as follows:

Hepatic: elevated direct bilirubin <1%; GGT <1%; SGOT (AST) <1%; SGPT (ALT) <1%, Renal: elevated serum creatinine <1%.
Less Frequent Adverse Reactions Observed During Clinical Trials of Clarithromycin

Based on pooled data across all indications, the following adverse reactions were observed in clinical trials with clarithromycin at a rate less than 1%:

**Blood and Lymphatic System Disorders:** Leukopenia, neutropenia, thrombocythemia, eosinophilia

**Cardiac Disorders:** Electrocardiogram QT prolonged, cardiac arrest, atrial fibrillation, extrasystoles, palpitations

**Ear and Labyrinth Disorders:** Vertigo, tinnitus, hearing impaired

**Gastrointestinal Disorders:** Stomatitis, glossitis, esophagitis, gastroesophageal reflux disease, gastritis, proctalgia, abdominal distension, constipation, dry mouth, eructation, flatulence

**General Disorders and Administration Site Conditions:** Malaise, pyrexia, asthenia, chest pain, chills, fatigue

**Hepatobiliary Disorders:** Cholestasis, hepatitis

**Immune System Disorders:** Hypersensitivity

**Infections and Infestations:** Cellulitis, gastroenteritis, infection, vaginal infection

**Investigations:** Blood bilirubin increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, albumin globulin ratio abnormal

**Metabolism and Nutrition Disorders:** Anorexia, decreased appetite

**Musculoskeletal and Connective Tissue Disorders:** Myalgia, muscle spasms, nuchal rigidity

**Nervous System Disorders:** Dizziness, tremor, loss of consciousness, dyskinesia, somnolence

**Psychiatric Disorders:** Anxiety, nervousness

**Renal and Urinary Disorders:** Blood creatinine increased, blood urea increased

**Respiratory, Thoracic and Mediastinal Disorders:** Asthma, epistaxis, pulmonary embolism

**Skin and Subcutaneous Tissue Disorders:** Urticaria, dermatitis bullous, pruritus, hyperhidrosis, rash maculo-papular

**Gastrointestinal Adverse Reactions**

In the acute exacerbation of chronic bronchitis and acute maxillary sinusitis studies overall gastrointestinal adverse reactions were reported by a similar proportion of patients taking either clarithromycin tablets or clarithromycin extended-release tablets; however, patients taking clarithromycin extended-release tablets reported significantly less severe gastrointestinal symptoms compared to patients taking clarithromycin tablets. In addition, patients taking clarithromycin extended-release tablets had significantly fewer premature discontinuations for drug-related gastrointestinal or abnormal taste adverse reactions compared to clarithromycin tablets.

**All-Cause Mortality in Patients with Coronary Artery Disease 1 to 10 Years Following Clarithromycin Exposure**

In one clinical trial evaluating treatment with clarithromycin on outcomes in patients with coronary artery disease, an increase in risk of all-cause mortality was observed in patients randomized to clarithromycin. Clarithromycin for treatment of coronary artery disease is not an approved indication. Patients were treated with clarithromycin or placebo for 14 days and observed for primary outcome events (e.g., all-cause mortality or non-fatal cardiac events) for several years. A numerically higher number of primary outcome events in patients randomized to receive clarithromycin was observed with a hazard ratio of 1.06 (95% confidence interval 0.98 to 1.14). However, at follow-up 10 years post-treatment, there were 866 (40%) deaths in the clarithromycin group and 815 (37%) deaths in the placebo group that represented a hazard ratio for all-cause mortality of 1.10 (95% confidence interval 1.00 to
1.21). The difference in the number of deaths emerged after one year or more after the end of treatment. The cause of the difference in all-cause mortality has not been established. Other epidemiologic studies evaluating this risk have shown variable results [see Warnings and Precautions (5.5)].

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of clarithromycin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood and Lymphatic System: Thrombocytopenia, agranulocytosis
Cardiac: Ventricular arrhythmia, ventricular tachycardia, torsades de pointes
Ear and Labyrinth: Deafness was reported chiefly in elderly women and was usually reversible.
Gastrointestinal: Pancreatitis acute, tongue discoloration, tooth discoloration was reported and was usually reversible with professional cleaning upon discontinuation of the drug.

There have been reports of clarithromycin extended-release tablets in the stool, many of which have occurred in patients with anatomic (including ileostomy or colostomy) or functional gastrointestinal disorders with shortened GI transit times. In several reports, tablet residues have occurred in the context of diarrhea. It is recommended that patients who experience tablet residue in the stool and no improvement in their condition should be switched to a different clarithromycin formulation (e.g. suspension) or another antibacterial drug.

Hepatobiliary: Hepatic failure, jaundice hepatocellular. Adverse reactions related to hepatic dysfunction have been reported with clarithromycin [see Warnings and Precautions (5.2)].

Infections and Infestations: Pseudomembranous colitis [see Warnings and Precautions (5.6)]

Immune System: Anaphylactic reactions, angioedema

Investigations: Prothrombin time prolonged, white blood cell count decreased, international normalized ratio increased. Abnormal urine color has been reported, associated with hepatic failure.

Metabolism and Nutrition: Hypoglycemia has been reported in patients taking oral hypoglycemic agents or insulin.

Musculoskeletal and Connective Tissue: Myopathy, rhabdomyolysis was reported and in some of the reports, clarithromycin was administered concomitantly with statins, fibrates, colchicine or allopurinol [see Contraindications (4.5) and Warnings and Precautions (5.4)].

Nervous System: Parosmia, anosmia, ageusia, paresthesia and convulsions
Psychiatric: Abnormal behavior, confusional state, depersonalization, disorientation, hallucination, depression, manic behavior, abnormal dream, psychotic disorder. These disorders usually resolve upon discontinuation of the drug.
Renal and Urinary: Nephritis interstitial, renal failure

Skin and Subcutaneous Tissue: Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), Henoch-Schonlein purpura, acne, acute generalized exanthematous pustulosis
Vascular: Hemorrhage

7 DRUG INTERACTIONS

Co-administration of clarithromycin is known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.
Clarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g., carbamazepine) and/or the substrate is extensively metabolized by this enzyme. Adjust dosage when appropriate and monitor serum concentrations of drugs primarily metabolized by CYP3A closely in patients concurrently receiving clarithromycin.

### Table 8: Clinically Significant Drug Interactions with Clarithromycin

<table>
<thead>
<tr>
<th>Drug(s) with Pharmacokinetics Affected by Clarithromycin</th>
<th>Recommendation</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiarrhythmics: Disopyramide</td>
<td>Not Recommended</td>
<td>Disopyramide, Quinidine: There have been postmarketing reports of <em>torsades de pointes</em> occurring with concurrent use of clarithromycin and quinidine or disopyramide. Electrocardiograms should be monitored for QTc prolongation during coadministration of clarithromycin with these drugs [see Warnings and Precautions (5.3)] . Serum concentrations of these medications should also be monitored. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with disopyramide and quinidine. There have been postmarketing reports of hypoglycemia with the concomitant administration of clarithromycin and disopyramide. Therefore, blood glucose levels should be monitored during concomitant administration of clarithromycin and disopyramide.</td>
</tr>
<tr>
<td>Quinidine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dofetilide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amiodarone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sotalol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procainamide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digoxin</td>
<td>Use With Caution</td>
<td>Digoxin: Digoxin is a substrate for P-glycoprotein (Pgp) and clarithromycin is known to inhibit Pgp. When clarithromycin and digoxin are co-administered, inhibition of Pgp by clarithromycin may lead to increased exposure of digoxin. Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin concomitantly have been reported in postmarketing surveillance. Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias. Monitoring of serum digoxin concentrations should be considered, especially for patients with digoxin concentrations in the upper therapeutic range.</td>
</tr>
<tr>
<td>Oral Anticoagulants:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Use/Dose Adjustment</td>
<td>Interaction Description</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Warfarin</td>
<td>Use With Caution</td>
<td>Oral anticoagulants: Spontaneous reports in the postmarketing period suggest that concomitant administration of clarithromycin and oral anticoagulants may potentiate the effects of the oral anticoagulants. Prothrombin times should be carefully monitored while patients are receiving clarithromycin and oral anticoagulants simultaneously [see Warnings and Precautions (5.4)] .</td>
</tr>
<tr>
<td>Antiepileptics:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>Use With Caution</td>
<td>Carbamazepine: Concomitant administration of single doses of clarithromycin and carbamazepine has been shown to result in increased plasma concentrations of carbamazepine. Blood level monitoring of carbamazepine may be considered. Increased serum concentrations of carbamazepine were observed in clinical trials with clarithromycin. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with carbamazepine.</td>
</tr>
<tr>
<td>Antifungals:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Itraconazole</td>
<td>Use With Caution</td>
<td>Itraconazole: Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A, potentially leading to a bi-directional drug interaction when administered concomitantly (see also Itraconazole under “Drugs That Affect Clarithromycin” in the table below). Clarithromycin may increase the plasma concentrations of itraconazole. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged adverse reactions.</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>No Dose Adjustment</td>
<td>Fluconazole: [see Pharmacokinetics (12.3)]</td>
</tr>
<tr>
<td>Anti-Gout Agents:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colchicine (in patients with renal or hepatic impairment)</td>
<td>Contraindicated</td>
<td>Colchicine: Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (Pgp). Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. The dose of colchicine should be reduced when co-administered with clarithromycin in patients with normal renal and hepatic function [see</td>
</tr>
<tr>
<td>with normal renal and hepatic function</td>
<td>Use With Caution</td>
<td>Contraindications (4.4) and Warnings and Precautions (5.4)</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-----------------</td>
<td>----------------------------------------------------------</td>
</tr>
</tbody>
</table>

### Antipsychotics:

<table>
<thead>
<tr>
<th>Pimozide</th>
<th>Contraindicated</th>
<th>Pimozide: [See Contraindications (4.2)]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quetiapine</td>
<td>Quetiapine: Quetiapine is a substrate for CYP3A4, which is inhibited by clarithromycin. Co-administration with clarithromycin could result in increased quetiapine exposure and possible quetiapine related toxicities. There have been postmarketing reports of somnolence, orthostatic hypotension, altered state of consciousness, neuroleptic malignant syndrome, and QT prolongation during concomitant administration. Refer to quetiapine prescribing information for recommendations on dose reduction if co-administered with CYP3A4 inhibitors such as clarithromycin.</td>
<td></td>
</tr>
</tbody>
</table>

### Antispasmodics:

<table>
<thead>
<tr>
<th>Tolterodine (patients deficient in CYP2D6 activity)</th>
<th>Use With Caution</th>
<th>Tolterodine: The primary route of metabolism for tolterodine is via CYP2D6. However, in a subset of the population devoid of CYP2D6, the identified pathway of metabolism is via CYP3A. In this population subset, inhibition of CYP3A results in significantly higher serum concentrations of tolterodine. Tolterodine 1 mg twice daily is recommended in patients deficient in CYP2D6 activity (poor metabolizers) when co-administered with clarithromycin.</th>
</tr>
</thead>
</table>

### Antivirals:

<table>
<thead>
<tr>
<th>Atazanavir</th>
<th>Use With Caution</th>
<th>Atazanavir: Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction (see Atazanavir under “Drugs That Affect Clarithromycin” in the table below) [see Pharmacokinetics (12.3)].</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saquinavir (in patients with decreased renal function)</td>
<td></td>
<td>Saquinavir: Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A and there is evidence of a bi-directional drug interaction (see Saquinavir under “Drugs That Affect Clarithromycin” in the table below) [see Pharmacokinetics (12.3)].</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>--------------------------</td>
<td>------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Ritonavir</strong>&lt;br&gt;<strong>Etravirine</strong></td>
<td><strong>Ritonavir, Etravirine:</strong> (see Ritonavir and Etravirine under “Drugs That Affect Clarithromycin” in the table below) [see Pharmacokinetics (12.3)].</td>
<td><strong>Maraviroc:</strong> Clarithromycin may result in increases in maraviroc exposures by inhibition of CYP3A metabolism. See Selzentry® prescribing information for dose recommendation when given with strong CYP3A inhibitors such as clarithromycin.</td>
</tr>
<tr>
<td><strong>Maraviroc</strong></td>
<td><strong>Maraviroc:</strong> Clarithromycin may result in increases in maraviroc exposures by inhibition of CYP3A metabolism. See Selzentry® prescribing information for dose recommendation when given with strong CYP3A inhibitors such as clarithromycin.</td>
<td><strong>Boceprevir (in patients with normal renal function):</strong> Boceprevir: Both clarithromycin and boceprevir are substrates and inhibitors of CYP3A, potentially leading to a bi-directional drug interaction when co-administered. No dose adjustments are necessary for patients with normal renal function (see Victrelis® prescribing information).</td>
</tr>
<tr>
<td><strong>Didanosine</strong></td>
<td><strong>No Dose Adjustment</strong></td>
<td><strong>Zidovudine:</strong> Simultaneous oral administration of clarithromycin immediate-release tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations. Administration of clarithromycin and zidovudine should be separated by at least two hours [see Pharmacokinetics (12.3)]. The impact of co-administration of clarithromycin extended-release tablets or granules and zidovudine has not been evaluated.</td>
</tr>
<tr>
<td><strong>Calcium Channel Blockers:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Verapamil</strong></td>
<td><strong>Use With Caution</strong></td>
<td><strong>Verapamil:</strong> Hypotension, bradyarrhythmias, and lactic acidosis have been observed in patients receiving concurrent verapamil, [see Warnings and Precautions (5.4)].</td>
</tr>
<tr>
<td><strong>Amlodipine</strong>&lt;br&gt;<strong>Diltiazem</strong></td>
<td><strong>Amlodipine, Diltiazem:</strong> [see Warnings and Precautions (5.4)]</td>
<td></td>
</tr>
<tr>
<td><strong>Nifedipine</strong></td>
<td><strong>Nifedipine:</strong> Nifedipine is a substrate for CYP3A. Clarithromycin and other macrolides are known to inhibit CYP3A. There is potential of CYP3A-mediated interaction between nifedipine and clarithromycin.</td>
<td></td>
</tr>
</tbody>
</table>
Hypotension and peripheral edema were observed when clarithromycin was taken concomitantly with nifedipine [see Warnings and Precautions (5.4)].

<table>
<thead>
<tr>
<th>Ergot Alkaloids:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ergotamine</td>
<td>Contraindicated</td>
</tr>
<tr>
<td>Dihydroergotamine</td>
<td></td>
</tr>
</tbody>
</table>

| Gastroprokinetic Agents: |  |
|--------------------------|-----------------
| Cisapride                | Contraindicated |
|                          | Cisapride:[See Contraindications (4.2)] |

| Lipid-lowering agents: |  |
|------------------------|-----------------
| Lomitapide             | Contraindicated |
| Lovastatin             |  |
| Simvastatin            |  |
|                         | Lomitapide, Lovastatin, Simvastatin: Clarithromycin may increase the exposure of these drugs by inhibition of CYP3A metabolism, thereby increasing the risk of toxicities from these drugs [See Contraindications (4.5) and Warnings and Precautions (5.4)]. |
| Atorvastatin           | Use With Caution |
| Pravastatin            |  |
|                         | Atorvastatin, Pravastatin, Fluvastatin: [See Warnings and Precautions (5.4)] |
| Fluvastatin            | No Dose Adjustment |

| Hypoglycemic Agents: |  |
|---------------------|-----------------
<p>| Nateglinide         | Use With Caution |
| Pioglitazone        |  |
| Repaglinide         |  |
| Rosiglitazone       |  |
|                       | Nateglinide, Pioglitazone, Repaglinide, Rosiglitazone:[See Warnings and Precautions (5.4) and Adverse Reactions (6.2)] |
| Insulin              |  |
|                       | Insulin:[See Warnings and Precautions (5.4) and Adverse Reactions (6.2)] |</p>
<table>
<thead>
<tr>
<th>Immunosuppressants:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclosporine</td>
<td>Use With Caution</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Phosphodiesterase inhibitors:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sildenafil</td>
<td>Use With Caution</td>
</tr>
<tr>
<td>Tadalafil</td>
<td></td>
</tr>
<tr>
<td>Vardenafil</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Proton Pump Inhibitors:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Omeprazole</td>
<td>No Dose Adjustment</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Xanthine Derivatives:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Theophylline</td>
<td>Use With Caution</td>
</tr>
<tr>
<td>Drug Class</td>
<td>Comment</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>----------------------------------------------</td>
</tr>
<tr>
<td>Triazolobenzodiazepines and Other Related</td>
<td>Use With Caution</td>
</tr>
<tr>
<td>Benzodiazepines:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Midazolam</td>
<td>Use With Caution</td>
</tr>
<tr>
<td>Alprazolam</td>
<td></td>
</tr>
<tr>
<td>Triazolam</td>
<td></td>
</tr>
<tr>
<td>Alprazolam</td>
<td></td>
</tr>
<tr>
<td>Triazolam</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Temazepam, Nitrazepam, Lorazepam</td>
<td>No Dose Adjustment</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytochrome P450 Inducers:</td>
<td>Use With Caution</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Drugs Metabolized by CYP3A:</td>
<td>Use With Caution</td>
</tr>
</tbody>
</table>

Baseline concentrations in the upper therapeutic range.
Bromocriptine  
Cilostazol  
Methylprednisolone  
Vinblastine  
Phenobarbital  
St. John’s Wort

CYP3A based interactions of clarithromycin with alfentanil, methylprednisolone, cilostazol, bromocriptine, vinblastine, phenobarbital, and St. John’s Wort.

Other Drugs Metabolized by CYP450 Isoforms Other than CYP3A:

- Hexobarbital  
- Phenytoin  
- Valproate

Use With Caution

There have been postmarketing reports of interactions of clarithromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.

### Drugs that Affect Clarithromycin

<table>
<thead>
<tr>
<th>Drug(s) that Affect the Pharmacokinetics of Clarithromycin</th>
<th>Recommendation</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antifungals:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Itraconazole</td>
<td>Use With Caution</td>
<td>Itraconazole: Itraconazole may increase the plasma concentrations of clarithromycin. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged adverse reactions (see also Itraconazole under “Drugs That Are Affected By Clarithromycin” in the table above).</td>
</tr>
<tr>
<td>Antivirals:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atazanavir</td>
<td>Use With Caution</td>
<td>Atazanavir: When clarithromycin is co-administered with atazanavir, the dose of clarithromycin should be decreased by 50% [see Clinical Pharmacology (12.3)] . Since concentrations of 14-OH clarithromycin are significantly reduced when clarithromycin is co-administered with atazanavir, alternative antibacterial therapy should be considered for indications other than infections due to Mycobacterium avium complex. Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors.</td>
</tr>
<tr>
<td>Drug</td>
<td>Description</td>
<td>Notes</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
<td>------</td>
</tr>
<tr>
<td><strong>Ritonavir (in patients with decreased renal function)</strong></td>
<td><strong>Ritonavir:</strong> Since concentrations of 14-OH clarithromycin are significantly reduced when clarithromycin is co-administered with ritonavir, alternative antibacterial therapy should be considered for indications other than infections due to <em>Mycobacterium avium</em> [see Pharmacokinetics (12.3)].</td>
<td></td>
</tr>
<tr>
<td><strong>Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors.</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Saquinavir (in patients with decreased renal function)</strong></td>
<td><strong>Saquinavir:</strong> When saquinavir is co-administered with ritonavir, consideration should be given to the potential effects of ritonavir on clarithromycin (refer to ritonavir above) [see Pharmacokinetics (12.3)].</td>
<td></td>
</tr>
<tr>
<td><strong>Etravirine</strong></td>
<td><strong>Etravirine:</strong> Clarithromycin exposure was decreased by etravirine; however, concentrations of the active metabolite, 14-OH-clarithromycin, were increased. Because 14-OH-clarithromycin has reduced activity against <em>Mycobacterium avium</em> complex (MAC), overall activity against this pathogen may be altered; therefore alternatives to clarithromycin should be considered for the treatment of MAC.</td>
<td></td>
</tr>
<tr>
<td><strong>Saquinavir (in patients with normal renal function)</strong></td>
<td>No Dose Adjustment</td>
<td></td>
</tr>
<tr>
<td><strong>Ritonavir (in patients with normal renal function)</strong></td>
<td>Proton Pump Inhibitors:</td>
<td></td>
</tr>
<tr>
<td><strong>Proton Pump Inhibitors:</strong></td>
<td>Omeprazole</td>
<td><strong>Omeprazole:</strong> Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole [see Pharmacokinetics (12.3)].</td>
</tr>
<tr>
<td><strong>Miscellaneous Cytochrome P450 Inducers:</strong></td>
<td><strong>Efavirenz</strong></td>
<td>Use With Caution</td>
</tr>
<tr>
<td><strong>Nevirapine</strong></td>
<td><strong>Rifampicin</strong></td>
<td>Inducers of CYP3A enzymes, such as efavirenz, nevirapine, rifampicin, rifabutin, and rifapentine will increase the metabolism of clarithromycin, thus</td>
</tr>
</tbody>
</table>
8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Based on findings from animal studies, clarithromycin is not recommended for use in pregnant women except in clinical circumstances where no alternative therapy is appropriate. If pregnancy occurs while taking clarithromycin, the patient should be apprised of the potential hazard to the fetus [see Warnings and Precautions (5.7)].

Limited data from a small number of published human studies with clarithromycin use during pregnancy are insufficient to inform drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, administration of oral clarithromycin to pregnant mice, rats, rabbits, and monkeys during the period of organogenesis produced malformations in rats (cardiovascular anomalies) and mice (cleft palate) at clinically relevant doses based on body surface area comparison. Fetal effects in mice, rats, and monkeys (e.g., reduced fetal survival, body weight, body weight gain) and implantation losses in rabbits were generally considered to be secondary to maternal toxicity (see Data).

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

Animal reproduction studies were conducted in mice, rats, rabbits, and monkeys with oral and intravenously administered clarithromycin. In pregnant mice, clarithromycin was administered during organogenesis (gestation day [GD] 6 to 15) at oral doses of 15, 60, 250, 500, or 1000 mg/kg/day. Reduced body weight observed in dams at 1000 mg/kg/day (3 times the maximum recommended human dose [MRHD] based on body surface area comparison) resulted in reduced survival and body weight of the fetuses. At ≥ 500 mg/kg/day, increases in the incidence of post-implantation loss and cleft palate in the fetuses were observed. No adverse developmental effects were observed in mice at ≤ 250 mg/kg/day (≤ 1 times MRHD based on body surface area comparison).

In pregnant Sprague Dawley rats, clarithromycin was administered during organogenesis (GD 6 to 15) at oral doses of 15, 50, or 150 mg/kg/day. Reductions in body weight and food consumption was observed in dams at 150 mg/kg/day. Increased resorptions and reduced body weight of the fetuses at this dose were considered secondary to maternal toxicity. Additionally, at 150 mg/kg/day (1 times MRHD based on body surface area comparison), a low incidence of cardiovascular anomalies (complete situs inversus, undivided truncus, IV septal defect) was observed in the fetuses. Clarithromycin did not cause
adverse developmental effects in rats at 50 mg/kg/day (0.3 times MRHD based on body surface area comparison). Intravenous dosing of clarithromycin during organogenesis in rats (GD 6 to 15) at 15, 50, or 160 mg/kg/day was associated with maternal toxicity (reduced body weight, body-weight gain, and food consumption) at 160 mg/kg/day but no evidence of adverse developmental effects at any dose (≤ 1 times MRHD based on body surface area comparison).

In pregnant Wistar rat, clarithromycin was administered during organogenesis (GD 7 to 17) at oral doses of 10, 40, or 160 mg/kg/day. Reduced body weight and food consumption were observed in dams at 160 mg/kg/day but there was no evidence of adverse developmental effects at any dose (≤ 1 times MRHD based on body surface area comparison).

In pregnant rabbits, clarithromycin administered during organogenesis (GD 6 to 18) at oral doses of 10, 35, or 125 mg/kg/day resulted in reduced maternal food consumption and decreased body weight at the highest dose, with no evidence of any adverse developmental effects at any dose (≤ 2 times MRHD based on body surface area comparison). Intravenously administered clarithromycin to pregnant rabbits during organogenesis (GD 6 to 18) in rabbits at 20, 40, 80, or 160 mg/kg/day (≥ 0.3 times MRHD based on body surface area comparison) resulted in maternal toxicity and implantation losses at all doses.

In pregnant monkeys, clarithromycin was administered (GD 20 to 50) at oral doses of 35 or 70 mg/kg/day. Dose-dependent emesis, poor appetite, fecal changes, and reduced body weight were observed in dams at all doses (≥ 0.5 times MRHD based on body surface area comparison).

Growth retardation in 1 fetus at 70 mg/kg/day was considered secondary to maternal toxicity. There was no evidence of primary drug related adverse developmental effects at any dose tested.

In a reproductive toxicology study in rats administered oral clarithromycin late in gestation through lactation (GD 17 to post-natal day 21) at doses of 10, 40, or 160 mg/kg/day (≤ 1 times MRHD based on body surface area comparison), reductions in maternal body weight and food consumption were observed at 160 mg/kg/day. Reduced body-weight gain observed in offspring at 160 mg/kg/day was considered secondary to maternal toxicity. No adverse developmental effects were observed with clarithromycin at any dose tested.

8.2 Lactation
Risk Summary
Based on limited human data, clarithromycin and its active metabolite 14-OH clarithromycin are present in human milk at less than 2% of the maternal weight-adjusted dose (see Data). In a separate observational study, reported adverse effects on breast-fed children (rash, diarrhea, loss of appetite, somnolence) were comparable to amoxicillin (see Data). No data are available to assess the effects of clarithromycin or 14-OH clarithromycin on milk production.

The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for clarithromycin and any potential adverse effects on the breast-fed child from clarithromycin or from the underlying maternal condition.

Data
Human
Serum and milk samples were obtained after 3 days of treatment, at steady state, from one published study of 12 lactating women who were taking clarithromycin 250 mg orally twice daily. Based on the limited data from this study, and assuming milk consumption of 150 mL/kg/day, an exclusively human milk fed infant would receive an estimated average of 136 mcg/kg/day of clarithromycin and its active metabolite, with this maternal dosage regimen. This is less than 2% of the maternal weight-adjusted dose (7.8 mg/kg/day, based on the average maternal weight of 64 kg), and less than 1% of the pediatric dose (15 mg/kg/day) for children greater than 6 months of age.

A prospective observational study of 55 breastfed infants of mothers taking a macrolide antibacterial (6 were exposed to clarithromycin) were compared to 36 breastfed infants of mothers taking amoxicillin.
Adverse reactions were comparable in both groups. Adverse reactions occurred in 12.7% of infants exposed to macrolides and included rash, diarrhea, loss of appetite, and somnolence.

8.3 Females and Males of Reproductive Potential

Males

Administration of clarithromycin resulted in testicular atrophy in rats, dogs and monkeys [see Nonclinical Toxicology (13.1)].

8.4 Pediatric Use

The safety and effectiveness of clarithromycin extended-release tablets in the treatment of pediatric patients has not been established.

Safety and effectiveness of clarithromycin in pediatric patients under 6 months of age have not been established. The safety of clarithromycin has not been studied in MAC patients under the age of 20 months.

8.5 Geriatric Use

In a steady-state study in which healthy elderly subjects (65 years to 81 years of age) were given 500 mg of clarithromycin every 12 hours, the maximum serum concentrations and area under the curves of clarithromycin and 14-OH clarithromycin were increased compared to those achieved in healthy young adults. These changes in pharmacokinetics parallel known age-related decreases in renal function. In clinical trials, elderly patients did not have an increased incidence of adverse reactions when compared to younger patients. Consider dosage adjustment in elderly patients with severe renal impairment. Elderly patients may be more susceptible to development of torsades de pointes arrhythmias than younger patients [see Warnings and Precautions (5.3)].

Most reports of acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem, nifedipine) involved elderly patients 65 years of age or older [see Warnings and Precautions (5.4)].

Especially in elderly patients, there have been reports of colchicine toxicity with concomitant use of clarithromycin and colchicine, some of which occurred in patients with renal insufficiency. Deaths have been reported in some patients [see Contraindications (4.4) and Warnings and Precautions (5.4)].

8.6 Renal and Hepatic Impairment

Clarithromycin is principally excreted via the liver and kidney. Clarithromycin may be administered without dosage adjustment to patients with hepatic impairment and normal renal function. However, in the presence of severe renal impairment with or without coexisting hepatic impairment, decreased dosage or prolonged dosing intervals may be appropriate [see Dosage and Administration (2.5)].

10 OVERDOSAGE

Overdosage of clarithromycin can cause gastrointestinal symptoms such as abdominal pain, vomiting, nausea, and diarrhea.

Treat adverse reactions accompanying overdose by the prompt elimination of unabsorbed drug and supportive measures. As with other macrolides, clarithromycin serum concentrations are not expected to be appreciably affected by hemodialysis or peritoneal dialysis.

11 DESCRIPTION

Clarithromycin is a semi-synthetic macrolide antimicrobial for oral use. Chemically, it is 6-0-methylerythromycin. The molecular formula is C_{38}H_{69}NO_{13}, and the molecular weight is 747.96.
The structural formula is:

![Structural formula of Clarithromycin]

**Figure 1: Structure of Clarithromycin**

Clarithromycin is a white to off-white crystalline powder. It is soluble in acetone, slightly soluble in methanol, ethanol, and acetonitrile, and practically insoluble in water.

Clarithromycin is available as extended-release tablets.

Each white or off-white, capsular-shaped film-coated Clarithromycin Extended-release Tablets, USP contains 500 mg of clarithromycin and the following inactive ingredients: glyceryl dibehenate, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, and titanium dioxide.

Clarithromycin Extended-release Tablets, USP meets the dissolution specifications which were established according to the USP monograph-Clarithromycin Extended-release Tablets Test 2.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Clarithromycin is a macrolide antimicrobial drug [see Microbiology (12.4)].

12.3 Pharmacokinetics

Absorption

*Clarithromycin Immediate-Release Tablets*

The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%. For a single 500 mg dose of clarithromycin, food slightly delays the onset of clarithromycin absorption, increasing the peak time from approximately 2 to 2.5 hours. Food also increases the clarithromycin peak plasma concentration by about 24%, but does not affect the extent of clarithromycin bioavailability. Food does not affect the onset of formation of the active metabolite, 14-OH clarithromycin or its peak plasma concentration but does slightly decrease the extent of metabolite formation, indicated by an 11% decrease in area under the plasma concentration-time curve (AUC). Therefore, clarithromycin tablets may be given without regard to food. In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
Clarithromycin Extended-Release Tablets

Clarithromycin extended-release tablets provide extended absorption of clarithromycin from the gastrointestinal tract after oral administration. Relative to an equal total daily dose of immediate-release clarithromycin tablets, clarithromycin extended-release tablets provide lower and later steady-state peak plasma concentrations but equivalent 24-hour AUCs for both clarithromycin and its microbiologically-active metabolite, 14-OH clarithromycin. While the extent of formation of 14-OH clarithromycin following administration of clarithromycin extended-release tablets (2 x 500 mg tablets once daily) is not affected by food, administration under fasting conditions is associated with approximately 30% lower clarithromycin AUC relative to administration with food. Therefore, clarithromycin extended-release tablets should be taken with food.

Figure 2: Steady-State Clarithromycin Plasma Concentration-Time Profiles

Clarithromycin Granules For Oral Suspension

When 250 mg doses of clarithromycin as an oral suspension were administered to fasting healthy adult subjects, peak plasma concentrations were attained around 3 hours after dosing.

For adult patients, the bioavailability of 10 mL of the 125 mg/5 mL suspension or 10 mL of the 250 mg/5 mL suspension is similar to a 250 mg or 500 mg tablet, respectively.

In adults given 250 mg clarithromycin as suspension (n = 22), food appeared to decrease mean peak plasma clarithromycin concentrations from 1.2 (± 0.4) mcg/mL to 1.0 (± 0.4) mcg/mL and the extent of
absorption from 7.2 (± 2.5) hr•mcg/mL to 6.5 (± 3.7) hr•mcg/mL.

Distribution

Clarithromycin and the 14-OH clarithromycin metabolite distribute readily into body tissues and fluids. There are no data available on cerebrospinal fluid penetration. Because of high intracellular concentrations, tissue concentrations are higher than serum concentrations. Examples of tissue and serum concentrations are presented below.

<table>
<thead>
<tr>
<th>Tissue Type</th>
<th>Tissue (mcg/g)</th>
<th>Serum (mcg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tonsil</td>
<td>1.6</td>
<td>0.8</td>
</tr>
<tr>
<td>Lung</td>
<td>8.8</td>
<td>1.7</td>
</tr>
</tbody>
</table>

Metabolism and Elimination

**Clarithromycin Immediate-Release Tablets**

Steady-state peak plasma clarithromycin concentrations were attained within 3 days and were approximately 1 mcg/mL to 2 mcg/mL with a 250 mg dose administered every 12 hours and 3 mcg/mL to 4 mcg/mL with a 500 mg dose administered every 8 hours to 12 hours. The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours. The nonlinearity of clarithromycin pharmacokinetics is slight at the recommended doses of 250 mg and 500 mg administered every 8 hours to 12 hours. With a 250 mg every 12 hours dosing, the principal metabolite, 14-OH clarithromycin, attains a peak steady-state concentration of about 0.6 mcg/mL and has an elimination half-life of 5 hours to 6 hours. With a 500 mg every 8 hours to 12 hours dosing, the peak steady-state concentration of 14-OH clarithromycin is slightly higher (up to 1 mcg/mL), and its elimination half-life is about 7 hours to 9 hours. With any of these dosing regimens, the steady-state concentration of this metabolite is generally attained within 3 days to 4 days.

After a 250 mg tablet every 12 hours, approximately 20% of the dose is excreted in the urine as clarithromycin, while after a 500 mg tablet every 12 hours, the urinary excretion of clarithromycin is somewhat greater, approximately 30%. In comparison, after an oral dose of 250 mg (125 mg/5 mL) suspension every 12 hours, approximately 40% is excreted in urine as clarithromycin. The renal clearance of clarithromycin is, however, relatively independent of the dose size and approximates the normal glomerular filtration rate. The major metabolite found in urine is 14-OH clarithromycin, which accounts for an additional 10% to 15% of the dose with either a 250 mg or a 500 mg tablet administered every 12 hours.

**Clarithromycin Extended-Release Tablets**

In healthy human subjects, steady-state peak plasma clarithromycin concentrations of approximately 2 mcg/mL to 3 mcg/mL were achieved about 5 hours to 8 hours after oral administration of 1000 mg clarithromycin extended-release tablets once daily; for 14-OH clarithromycin, steady-state peak plasma concentrations of approximately 0.8 mcg/mL were attained about 6 hours to 9 hours after dosing. Steady-state peak plasma clarithromycin concentrations of approximately 1 mcg/mL to 2 mcg/mL were achieved about 5 hours to 6 hours after oral administration of a single 500 mg clarithromycin extended-release tablets once daily; for 14-OH clarithromycin, steady-state peak plasma concentrations of approximately 0.6 mcg/mL were attained about 6 hours after dosing.

Steady-state peak plasma concentrations were attained in 2 days to 3 days and were approximately 2 mcg/mL for clarithromycin and 0.7 mcg/mL for 14-OH clarithromycin when 250-mg doses of the clarithromycin suspension were administered every 12 hours. Elimination half-life of clarithromycin (3
hours to 4 hours) and that of 14-OH clarithromycin (5 hours to 7 hours) were similar to those observed at steady state following administration of equivalent doses of clarithromycin immediate-release tablets.

Specific Populations for Clarithromycin Immediate-release Tablets, Clarithromycin Extended-release Tablets, and Clarithromycin Granules Formulations

Clarithromycin Granules For Oral Suspension in Pediatric Patients

Clarithromycin penetrates into the middle ear fluid of pediatric patients with secretory otitis media.

Table 10. Middle Ear Fluid and Serum Concentrations of Clarithromycin and 14-OH-Clarithromycin in Pediatric Patients

<table>
<thead>
<tr>
<th>Analyte</th>
<th>Middle Ear Fluid (mcg/mL)</th>
<th>Serum (mcg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clarithromycin</td>
<td>2.5</td>
<td>1.7</td>
</tr>
<tr>
<td>14-OH Clarithromycin</td>
<td>1.3</td>
<td>0.8</td>
</tr>
</tbody>
</table>

When pediatric patients (n = 10) were administered a single oral dose of 7.5 mg/kg clarithromycin as an oral suspension, food increased mean peak plasma clarithromycin concentrations from 3.6 (± 1.5) mcg/mL to 4.6 (± 2.8) mcg/mL and the extent of absorption from 10.0 (± 5.5) hr•mcg/mL to 14.2 (± 9.4) hr•mcg/mL.

In pediatric patients requiring antibacterial therapy, administration of 7.5 mg/kg every 12 hours of clarithromycin as an oral suspension generally resulted in steady-state peak plasma concentrations of 3 mcg/mL to 7 mcg/mL for clarithromycin and 1 mcg/mL to 2 mcg/mL for 14-OH clarithromycin.

In HIV-infected pediatric patients taking 15 mg/kg of clarithromycin as an oral suspension every 12 hours, steady-state clarithromycin peak concentrations generally ranged from 6 mcg/mL to 15 mcg/mL.

HIV Infection

Steady-state concentrations of clarithromycin and 14-OH clarithromycin observed following administration of 500 mg doses of clarithromycin every 12 hours to adult patients with HIV infection were similar to those observed in healthy volunteers. In adult HIV-infected patients taking 500-mg or 1000-mg doses of clarithromycin every 12 hours, steady-state clarithromycin C_{max} values ranged from 2 mcg/mL to 4 mcg/mL and 5 mcg/mL to 10 mcg/mL, respectively.

Hepatic Impairment

The steady-state concentrations of clarithromycin in subjects with impaired hepatic function did not differ from those in normal subjects; however, the 14-OH clarithromycin concentrations were lower in the hepatically impaired subjects. The decreased formation of 14-OH clarithromycin was at least partially offset by an increase in renal clearance of clarithromycin in the subjects with impaired hepatic function when compared to healthy subjects.

Renal Impairment

The pharmacokinetics of clarithromycin was also altered in subjects with impaired renal function [see Use in Specific Populations (8.6)and Dosage and Administration (2.5)].

Drug Interactions

Fluconazole

Following administration of fluconazole 200 mg daily and clarithromycin 500 mg twice daily to 21 healthy volunteers, the steady-state clarithromycin C_{min} and AUC increased 33% and 18%, respectively. Clarithromycin exposures were increased and steady-state concentrations of 14-OH clarithromycin were not significantly affected by concomitant administration of fluconazole.
Colchicine
When a single dose of colchicine 0.6 mg was administered with clarithromycin 250 mg BID for 7 days, the colchicine C\textsubscript{max} increased 197% and the AUC \textsubscript{0-\infty} increased 239% compared to administration of colchicine alone.

Atazanavir
Following administration of clarithromycin (500 mg twice daily) with atazanavir (400 mg once daily), the clarithromycin AUC increased 94%, the 14-OH clarithromycin AUC decreased 70% and the atazanavir AUC increased 28%.

Ritonavir
Concomitant administration of clarithromycin and ritonavir (n = 22) resulted in a 77% increase in clarithromycin AUC and a 100% decrease in the AUC of 14-OH clarithromycin.

Saquinavir
Following administration of clarithromycin (500 mg bid) and saquinavir (soft gelatin capsules, 1200 mg tid) to 12 healthy volunteers, the steady-state saquinavir AUC and C\textsubscript{max} increased 177% and 187% respectively compared to administration of saquinavir alone. Clarithromycin AUC and C\textsubscript{max} increased 45% and 39% respectively, whereas the 14–OH clarithromycin AUC and C\textsubscript{max} decreased 24% and 34% respectively, compared to administration with clarithromycin alone.

Didanosine
Simultaneous administration of clarithromycin tablets and didanosine to 12 HIV-infected adult patients resulted in no statistically significant change in didanosine pharmacokinetics.

Zidovudine
Following administration of clarithromycin 500 mg tablets twice daily with zidovudine 100 mg every 4 hours, the steady-state zidovudine AUC decreased 12% compared to administration of zidovudine alone (n=4). Individual values ranged from a decrease of 34% to an increase of 14%. When clarithromycin tablets were administered two to four hours prior to zidovudine, the steady-state zidovudine C\textsubscript{max} increased 100% whereas the AUC was unaffected (n=24).

Omeprazole
Clarithromycin 500 mg every 8 hours was given in combination with omeprazole 40 mg daily to healthy adult subjects. The steady-state plasma concentrations of omeprazole were increased (C\textsubscript{max}, AUC \textsubscript{0-24}, and t\textsubscript{1/2} increases of 30%, 89%, and 34%, respectively), by the concomitant administration of clarithromycin.

The plasma levels of clarithromycin and 14–OH clarithromycin were increased by the concomitant administration of omeprazole. For clarithromycin, the mean C\textsubscript{max} was 10% greater, the mean C\textsubscript{min} was 27% greater, and the mean AUC \textsubscript{0-8} was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone. Similar results were seen for 14–OH clarithromycin, the mean C\textsubscript{max} was 45% greater, the mean C\textsubscript{min} was 57% greater, and the mean AUC \textsubscript{0-8} was 45% greater. Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole.

<table>
<thead>
<tr>
<th>Clarithromycin Tissue Concentrations 2 hours after Dose (mcg/mL)/(mcg/g)</th>
<th>Treatment</th>
<th>N</th>
<th>antrum</th>
<th>fundus</th>
<th>N</th>
<th>Mucus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clarithromycin</td>
<td>5</td>
<td></td>
<td>10.48 ± 2.01</td>
<td>20.81 ± 7.64</td>
<td>4</td>
<td>4.15 ± 7.74</td>
</tr>
<tr>
<td>Clarithromycin + Omeprazole</td>
<td>5</td>
<td></td>
<td>19.96 ± 4.71</td>
<td>24.25 ± 6.37</td>
<td>4</td>
<td>39.29 ± 32.79</td>
</tr>
</tbody>
</table>

Theophylline
In two studies in which theophylline was administered with clarithromycin (a theophylline sustained-release formulation was dosed at either 6.5 mg/kg or 12 mg/kg together with 250 or 500 mg q12h clarithromycin), the steady-state levels of $C_{\text{max}}$, $C_{\text{min}}$, and the area under the serum concentration time curve (AUC) of theophylline increased about 20%.

Midazolam

When a single dose of midazolam was co-administered with clarithromycin tablets (500 mg twice daily for 7 days), midazolam AUC increased 174% after intravenous administration of midazolam and 600% after oral administration.

For information about other drugs indicated in combination with clarithromycin, refer to their full prescribing information, CLINICAL PHARMACOLOGY section.

12.4 Microbiology

Mechanism of Action

Clarithromycin exerts its antibacterial action by binding to the 50S ribosomal subunit of susceptible bacteria resulting in inhibition of protein synthesis.

Resistance

The major routes of resistance are modification of the 23S rRNA in the 50S ribosomal subunit to insensitivity or drug efflux pumps. Beta-lactamase production should have no effect on clarithromycin activity.

Most isolates of methicillin-resistant and oxacillin-resistant staphylococci are resistant to clarithromycin.

Antimicrobial Activity

Clarithromycin has been shown to be active against most of the isolates of the following microorganisms both in vitro and in clinical infections [see Indications and Usage (1)].

Gram-Positive Bacteria
- Staphylococcus aureus
- Streptococcus pneumoniae
- Streptococcus pyogenes

Gram-Negative Bacteria
- Haemophilus influenzae
- Haemophilus parainfluenzae
- Moraxella catarrhalis

Other Microorganisms
- Chlamyphila pneumoniae
- Mycoplasma pneumoniae

At least 90 percent of the microorganisms listed below exhibit in vitro minimum inhibitory concentrations (MICs) less than or equal to the clarithromycin susceptible MIC breakpoint for organisms of similar type to those shown in Table 11. However, the efficacy of clarithromycin in treating clinical infections due to these microorganisms has not been established in adequate and well-controlled clinical trials.

Gram-Positive Bacteria
- Streptococcus agalactiae
- Streptococci (Groups C, F, G)
- Viridans group streptococci
Gram-Negative Bacteria
- *Legionella pneumophila*
- *Pasteurella multocida*

Anaerobic Bacteria
- *Clostridium perfringens*
- *Peptococcus niger*
- *Prevotella melaninogenica*
- *Propionibacterium acnes*

Susceptibility Testing Methods (Excluding Mycobacteria and Helicobacter)
For specific information regarding susceptibility test interpretive criteria, and associated test methods and quality control standards recognized by FDA for this drug, please see: http://www.fda.gov/STIC.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

**Mutagenesis**

The following *in vitro* mutagenicity tests have been conducted with clarithromycin:
- *Salmonella*/Mammalian Microsomes Test
- Bacterial Induced Mutation Frequency Test
- *In Vitro* Chromosome Aberration Test
- Rat Hepatocyte DNA Synthesis Assay
- Mouse Lymphoma Assay
- Mouse Dominant Lethal Study
- Mouse Micronucleus Test

All tests had negative results except the *in vitro* chromosome aberration test which was positive in one test and negative in another. In addition, a bacterial reverse-mutation test (Ames test) has been performed on clarithromycin metabolites with negative results.

**Impairment of Fertility**

Fertility and reproduction studies have shown that daily doses of up to 160 mg/kg/day to male and female rats caused no adverse effects on the estrous cycle, fertility, parturition, or number and viability of offspring. Plasma levels in rats after 150 mg/kg/day were twice the human serum levels.

Testicular atrophy occurred in rats at doses 7 times, in dogs at doses 3 times, and in monkeys at doses 8 times greater than the maximum human daily dose (on a body surface area basis).

13.2 Animal Toxicology and/or Pharmacology

Corneal opacity occurred in dogs at doses 12 times and in monkeys at doses 8 times greater than the maximum human daily dose (on a body surface area basis). Lymphoid depletion occurred in dogs at doses 3 times greater than and in monkeys at doses 2 times greater than the maximum human daily dose (on a body surface area basis).

15 REFERENCES


16 HOW SUPPLIED/STORAGE AND HANDLING

Clarithromycin Extended-release Tablets, USP are supplied as white or off-white, capsular-shaped film-coated 500 mg tablets debossed “S58” on one side and blank on the other side.

500 mg tablets:
Bottles of 60 NDC 0527-1930-06

Store Clarithromycin Extended-release Tablets, USP at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature].

17 PATIENT COUNSELING INFORMATION

Provide the following instructions or information about clarithromycin extended-release tablets to patients:

**Important Administration Instructions**
Advise patients that clarithromycin extended-release tablets should be taken with food.

**Drug Interactions**
Advise patients that clarithromycin may interact with some drugs; therefore, advise patients to report to their healthcare provider the use of any other medications.

**Diarrhea**
Advise patients that diarrhea is a common problem caused by antibacterials including clarithromycin which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial. If this occurs, instruct patients to contact their healthcare provider as soon as possible.

**Embryo-Fetal Toxicity**
Advise females of reproductive potential that if pregnancy occurs while taking this drug, there is a potential hazard to the fetus [see Warnings and Precautions (5.7) and Use in Specific Populations (8.1)].

**Antibacterial Resistance**
Counsel patients that antibacterial drugs including clarithromycin tablets should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When clarithromycin tablet is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by clarithromycin tablets or other antibacterial drugs in the future.

**Potential for Dizziness, Vertigo and Confusion**
There are no data on the effect of clarithromycin on the ability to drive or use machines. However, counsel patients regarding the potential for dizziness, vertigo, confusion and disorientation, which may occur with the clarithromycin tablets. The potential for these adverse reactions should be taken into account before patients drive or use machines.

**Risk of Mortality in Patients with Coronary Disease Years After clarithromycin Treatment**
Advise patients who have coronary artery disease to continue medications and lifestyle modifications
for their coronary artery disease because clarithromycin may be associated with increased risk for mortality years after the end of clarithromycin treatment.

* All trademark names are the property of their respective owners.

Manufactured by:
Sunshine Lake Pharma Co., Ltd.
No. 1, Northern Industry Road,
Northern Industry Park of Song Shan Lake
Dongguan 523808, Guangdong, China

Manufactured for:
Lannett Company Inc.
Philadelphia, PA 19136

L6832B
Rev. 11/19
5252
Clarithromycin Extended-release Tablets, USP
500 mg
Rx Only
## Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLARITHROMYCIN</td>
<td>CLARITHROMYCIN</td>
<td>500 mg</td>
</tr>
</tbody>
</table>

## Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLYCERYL DIBEHENATE</td>
<td></td>
</tr>
<tr>
<td>HYPROMELLOSES</td>
<td></td>
</tr>
<tr>
<td>LACTOSE MONOHYDRATE</td>
<td></td>
</tr>
<tr>
<td>MAGNESIUM STEARATE</td>
<td></td>
</tr>
<tr>
<td>POLYETHYLENE GLYCOL, UNSPECIFIED</td>
<td></td>
</tr>
<tr>
<td>TITANIUM DIOXIDE</td>
<td></td>
</tr>
</tbody>
</table>

## Product Characteristics

<table>
<thead>
<tr>
<th>Color</th>
<th>Score</th>
<th>Shape</th>
<th>Size</th>
<th>Flavor</th>
<th>Imprint Code</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>CAPSULE</td>
<td>19mm</td>
<td></td>
<td>S58</td>
</tr>
</tbody>
</table>

## Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0527-1930-06</td>
<td>60 in 1 BOTTLE; Type 0: Not a Combination Product</td>
<td>09/10/2019</td>
</tr>
</tbody>
</table>

## Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA</td>
<td>ANDA208987</td>
<td>09/10/2019</td>
</tr>
</tbody>
</table>

## Labeler - Lannett Company, Inc. (002277481)

## Registrant - HEC Pharm USA Inc. (962953530)

## Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunshine Lake Pharma Co., Ltd</td>
<td></td>
<td>545391443</td>
<td>manufacture(0527-1930)</td>
</tr>
</tbody>
</table>

Revised: 11/2019